ERBB2 and breast cancer: Twenty-seven patients (77.1%) carried TNBC without gBRCA mutations, while 2 (5.7%) patients carried gBRCA-mutant hormone receptor-positive (HR+)/HER2-negative BC and 6 (17.2%) gBRCA-mutant TNBC.